Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas V Faller

Showing results (91-100 of 126) with videos related to

Pageof 13
Sort By:
British Journal of Haematology|October 20, 2010
A randomized phase II trial of Arginine Butyrate with standard local therapy in refractory sickle cell leg ulcersLillian McMahon, Hannah Tamary, Melissa Askin, et al.
Journal of Clinical Pharmacology|March 23, 2011
Evaluation of safety and pharmacokinetics of sodium 2,2 dimethylbutyrate, a novel short chain fatty acid derivative, in a phase 1, double-blind, placebo-controlled, single-dose, and repeat-dose studies in healthy volunteersSusan P Perrine, William A Wargin, Michael S Boosalis, et al.
Haematologica|December 7, 2022
Time without transfusion reliance: a novel patient-centric metric for new therapies in myelodysplastic syndromesJoshua F Zeidner, Flora Mazerolle, Jonathan Norton, et al.
Cancer Prevention Research (Philadelphia, Pa.)|December 15, 2010
A vitamin D receptor-alkylating derivative of 1α,25-dihydroxyvitamin D3 inhibits growth of human kidney cancer cells and suppresses tumor growthJames R Lambert, Vikram J Eddy, Christian D Young, et al.
Vaccine|February 21, 2026
Safe and durable immune responses to a single dose DNA COVID-19 vaccine in previously vaccinated or SARS-CoV-2-infected adults: A phase 1 studyKhursheed Anwer, Lauren Musso, Ninaad Lasrado, et al.
Anticancer Research|July 25, 2008
Prostate 25-hydroxyvitamin D-1alpha-hydroxylase is up-regulated by suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitorLilin Wang, Kelly S Persons, Dan Jamieson, et al.
Clinical and Translational Science|January 27, 2021
Asia-inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trialXiaofei Zhou, Sharon Friedlander, Erik Kupperman, et al.
Clinical Pharmacology in Drug Development|November 16, 2022
Effect of Pevonedistat, an Investigational NEDD8-Activating Enzyme Inhibitor, on the QTc Interval in Patients With Advanced Solid TumorsXiaofei Zhou, Debra L Richardson, Afshin Dowlati, et al.
Bioresearch Open Access|August 3, 2018
A New Approach to Treating Neurodegenerative Otologic DisordersWalter H Moos, Douglas V Faller, Ioannis P Glavas, et al.
Bioresearch Open Access|January 2, 2018
Epigenetic Treatment of Neurodegenerative Ophthalmic Disorders: An Eye Toward the FutureWalter H Moos, Douglas V Faller, Ioannis P Glavas, et al.
Pageof 13

Showing results (91-100 of 126) with videos related to

Sort By:
Pageof 13
British Journal of Haematology|October 20, 2010
A randomized phase II trial of Arginine Butyrate with standard local therapy in refractory sickle cell leg ulcersLillian McMahon, Hannah Tamary, Melissa Askin, et al.
Journal of Clinical Pharmacology|March 23, 2011
Evaluation of safety and pharmacokinetics of sodium 2,2 dimethylbutyrate, a novel short chain fatty acid derivative, in a phase 1, double-blind, placebo-controlled, single-dose, and repeat-dose studies in healthy volunteersSusan P Perrine, William A Wargin, Michael S Boosalis, et al.
Haematologica|December 7, 2022
Time without transfusion reliance: a novel patient-centric metric for new therapies in myelodysplastic syndromesJoshua F Zeidner, Flora Mazerolle, Jonathan Norton, et al.
Cancer Prevention Research (Philadelphia, Pa.)|December 15, 2010
A vitamin D receptor-alkylating derivative of 1α,25-dihydroxyvitamin D3 inhibits growth of human kidney cancer cells and suppresses tumor growthJames R Lambert, Vikram J Eddy, Christian D Young, et al.
Vaccine|February 21, 2026
Safe and durable immune responses to a single dose DNA COVID-19 vaccine in previously vaccinated or SARS-CoV-2-infected adults: A phase 1 studyKhursheed Anwer, Lauren Musso, Ninaad Lasrado, et al.
Anticancer Research|July 25, 2008
Prostate 25-hydroxyvitamin D-1alpha-hydroxylase is up-regulated by suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitorLilin Wang, Kelly S Persons, Dan Jamieson, et al.
Clinical and Translational Science|January 27, 2021
Asia-inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trialXiaofei Zhou, Sharon Friedlander, Erik Kupperman, et al.
Clinical Pharmacology in Drug Development|November 16, 2022
Effect of Pevonedistat, an Investigational NEDD8-Activating Enzyme Inhibitor, on the QTc Interval in Patients With Advanced Solid TumorsXiaofei Zhou, Debra L Richardson, Afshin Dowlati, et al.
Bioresearch Open Access|August 3, 2018
A New Approach to Treating Neurodegenerative Otologic DisordersWalter H Moos, Douglas V Faller, Ioannis P Glavas, et al.
Bioresearch Open Access|January 2, 2018
Epigenetic Treatment of Neurodegenerative Ophthalmic Disorders: An Eye Toward the FutureWalter H Moos, Douglas V Faller, Ioannis P Glavas, et al.
Pageof 13